Skip to main content

Table 2 Reversal of MCT-Induced PAH by VIP, Bosentan, or Their Combination

From: VIP and endothelin receptor antagonist: An effective combination against experimental pulmonary arterial hypertension

Measurements Control, untreated MCT + P value (post hoc)
   0 VIP Bosentan VIP + Bosentan * **
RV systolic pressure (mm Hg) 24.3 ± 2.4 61.4 ± 4.8 33 ± 0.5 39 ± 1.2 26.0 ± 1.2 < 0.05 < 0.05 < 0.05
Arteriolar medial/luminal area 0.76 ± 0.07 3.9 ± 0.51 1.68 ± 0.19 1.76 ± 0.19 0.79 ± 0.05 < 0.05 < 0.05 < 0.05
RV/(LV+septum) weight ratio 0.26 ± 0.01 0.56 ± 0.03 0.51 ± 0.03 0.47 ± 0.07 0.34 ± 0.02 NS NS < 0.05
Lung inflammation (0-4) 0.20 ± 0.17 3.0 ± 0.26 0.3 ± 0.21 1.2 ± 0.28 0.3 ± 0.33 < 0.05 < 0.05 < 0.05
  1. Therapy with either drug, or both together, was begun 3 weeks following MCT, i.e., after PH had fully developed. ANOVA: p < 0.0001
  2. * MCT + VIP vs. MCT; † MCT + Bosentan vs. MCT; ** MCT + VIP + bosentan vs. MCT